Regenerx Biopharmaceuticals Inc (RGRX)

$0.00 0.00 (N/A)
Market Cap 0.00
Revenue (ttm) 80,000.00
Net Income (ttm) -1.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,162.50%
Debt to Equity Ratio 0.00
Volume 11,300
Avg Vol 2,280
Day's Range N/A - N/A
Shares Out 1.44M
Stochastic %K 0%
Beta 180.79
Analysts Strong Buy
Price Target $1.50

Company Profile

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceutical Group for the development and marketing of Tß4-related products; and HLB Therapeutics for the d...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 208 9191
Address:
15245 Shady Grove Road, Suite 470, Rockville, United States
12e456789o
12e456789o Mar. 6 at 7:04 PM
$RGRX Friday trading had HLB Thera move up instead of down. I'm now going to favor the alternative count even though it is not confirmed yet. The bottom could be in - IMO needs a close early next week above 2910....only 30 points away! Also noticed 11k+ (Million plus pre-split) shares traded yesterday with RGRX. Time to get out the popcorn :)
0 · Reply
12e456789o
12e456789o Mar. 5 at 8:11 PM
$RGRX HLB Thera - Most likely one last wave down Friday (but could be finished)
0 · Reply
12e456789o
12e456789o Feb. 25 at 8:43 PM
$RGRX Good news/bad news. Bad news - wave 1/2 pattern broke when 2870 was penetrated a second time. Confirmed with 2770 close. Good news - It is still a flat with a 3-3-5 pattern instead of ABC-X-ABC. Here is the long term view.
1 · Reply
12e456789o
12e456789o Feb. 13 at 9:04 PM
$RGRX This week saw two more waves put in with a net loss of 10pts. This last wave is a 5 wave structure just like the first wave down so this has to be a simple ABC zigzag with the irregular wave labeled as B instead of X. "Monitor and adjust" Still think this is waves 1 and 2 of the new bull but IMO the chart is at max tension and cannot accommodate any more waves down.
1 · Reply
12e456789o
12e456789o Feb. 6 at 6:02 PM
$RGRX The corrective wave 2 morphed into a double zigzag (WXY) or abc-X-abc. Using a bar chart to show the first move down is actually a diagonal. This is allowed with Elliott Wave. Then you have the irregular X wave. Final wave down is a simple 3 wave structure and the last leg of it creates a positive divergence with the daily RSI 5 (bottom of the chart). Confirmation will be a move to close above the ema 13 which is currently at 3085. With a move up next week we will finally be in wave 3 and it should start moving explosively soon. Close below 2770 invalidates this count.
0 · Reply
12e456789o
12e456789o Jan. 30 at 7:37 AM
$RGRX HLB Thera - Chart from last week had Jan 21st low as either wave 2 or A. Ended up being the A wave of an irregular flat. Wave 2 is complete now.
0 · Reply
12e456789o
12e456789o Jan. 22 at 9:10 PM
$RGRX HLB Thera - 5 up off the low to create wave 1. Wave 2 now likely complete. Wave 3 targets 4200 area (minimum)
0 · Reply
12e456789o
12e456789o Dec. 23 at 10:54 PM
$RGRX HLB Thera got a 2770 close on 12/18 so the multi year flat is complete. Looking for a positive divergence with the daily RSI 5 so most likely there will be one more mini swoon down to 2770 or a little lower in the next few days before the bottom is complete. 2026 looking inviting.
0 · Reply
dontu1dr
dontu1dr Nov. 27 at 10:31 PM
$RGRX Maybe Regenerx should consider partnering up with HLB in some form or another as HLB looks like they are good at getting things accomplished in the biotech industry? They seem to be a biotech on the move. THE DONKER
0 · Reply
dontu1dr
dontu1dr Nov. 26 at 1:30 PM
$RGRX if you go to the US CLINICAL TRIAL #: NCT05555589 and look at the changes that were made on: 10/21/25 (you can do this on the "record history tab" folks) Regentree made the following changes in OCTOBER 2025 Primary Completion 2025-12-31 [Estimated] Study Completion 2026-02-28 [Estimated] ASK yourself why they would be that accurate in the short term? that's a bit of a TELL, folks... It looks like they are "understating" their progress a bit to the public and being a bit more "accurate" in the clinical trial info in both the US & EUROPE. But that kinda "par for the course in biotech" at this point in the adventure... THE DONKER
1 · Reply
Latest News on RGRX
No data available.
12e456789o
12e456789o Mar. 6 at 7:04 PM
$RGRX Friday trading had HLB Thera move up instead of down. I'm now going to favor the alternative count even though it is not confirmed yet. The bottom could be in - IMO needs a close early next week above 2910....only 30 points away! Also noticed 11k+ (Million plus pre-split) shares traded yesterday with RGRX. Time to get out the popcorn :)
0 · Reply
12e456789o
12e456789o Mar. 5 at 8:11 PM
$RGRX HLB Thera - Most likely one last wave down Friday (but could be finished)
0 · Reply
12e456789o
12e456789o Feb. 25 at 8:43 PM
$RGRX Good news/bad news. Bad news - wave 1/2 pattern broke when 2870 was penetrated a second time. Confirmed with 2770 close. Good news - It is still a flat with a 3-3-5 pattern instead of ABC-X-ABC. Here is the long term view.
1 · Reply
12e456789o
12e456789o Feb. 13 at 9:04 PM
$RGRX This week saw two more waves put in with a net loss of 10pts. This last wave is a 5 wave structure just like the first wave down so this has to be a simple ABC zigzag with the irregular wave labeled as B instead of X. "Monitor and adjust" Still think this is waves 1 and 2 of the new bull but IMO the chart is at max tension and cannot accommodate any more waves down.
1 · Reply
12e456789o
12e456789o Feb. 6 at 6:02 PM
$RGRX The corrective wave 2 morphed into a double zigzag (WXY) or abc-X-abc. Using a bar chart to show the first move down is actually a diagonal. This is allowed with Elliott Wave. Then you have the irregular X wave. Final wave down is a simple 3 wave structure and the last leg of it creates a positive divergence with the daily RSI 5 (bottom of the chart). Confirmation will be a move to close above the ema 13 which is currently at 3085. With a move up next week we will finally be in wave 3 and it should start moving explosively soon. Close below 2770 invalidates this count.
0 · Reply
12e456789o
12e456789o Jan. 30 at 7:37 AM
$RGRX HLB Thera - Chart from last week had Jan 21st low as either wave 2 or A. Ended up being the A wave of an irregular flat. Wave 2 is complete now.
0 · Reply
12e456789o
12e456789o Jan. 22 at 9:10 PM
$RGRX HLB Thera - 5 up off the low to create wave 1. Wave 2 now likely complete. Wave 3 targets 4200 area (minimum)
0 · Reply
12e456789o
12e456789o Dec. 23 at 10:54 PM
$RGRX HLB Thera got a 2770 close on 12/18 so the multi year flat is complete. Looking for a positive divergence with the daily RSI 5 so most likely there will be one more mini swoon down to 2770 or a little lower in the next few days before the bottom is complete. 2026 looking inviting.
0 · Reply
dontu1dr
dontu1dr Nov. 27 at 10:31 PM
$RGRX Maybe Regenerx should consider partnering up with HLB in some form or another as HLB looks like they are good at getting things accomplished in the biotech industry? They seem to be a biotech on the move. THE DONKER
0 · Reply
dontu1dr
dontu1dr Nov. 26 at 1:30 PM
$RGRX if you go to the US CLINICAL TRIAL #: NCT05555589 and look at the changes that were made on: 10/21/25 (you can do this on the "record history tab" folks) Regentree made the following changes in OCTOBER 2025 Primary Completion 2025-12-31 [Estimated] Study Completion 2026-02-28 [Estimated] ASK yourself why they would be that accurate in the short term? that's a bit of a TELL, folks... It looks like they are "understating" their progress a bit to the public and being a bit more "accurate" in the clinical trial info in both the US & EUROPE. But that kinda "par for the course in biotech" at this point in the adventure... THE DONKER
1 · Reply
dontu1dr
dontu1dr Nov. 23 at 7:10 PM
$RGRX NOTE*** THIS IS RELEVANT: https://dealsite.co.kr/articles/151910 SUMMED up: HLB Therapeutics Co.,Ltd. announced a private placement to issue 1% Series 20 Unregistered Unsecured Private Convertible Bonds due December 4, 2028 for gross proceeds of KRW 17,000,000,000 on November 20, 2025. The company said, "The funds raised will be used for clinical trials of NK treatment and operating funds." -sometimes in PHARMA, they'll do a PIPE two or three months before a deal of some sort... -things could get interesting, maybe sooner than later. THE DONKER
0 · Reply
dontu1dr
dontu1dr Nov. 20 at 1:02 PM
$RGRX Read the following article: HLB Therapeutics Secures European Patent for RGN-259 Manufacturing Process, Announces IP System PATENTS are "life blood" of BIOPHARMA POINTS OF INTEREST: -Currently, HLB Therapeutics is proceeding smoothly with its Phase 3 clinical trial (SEER-2) for a neurotrophic keratitis (NK) treatment, centered on clinical sites in the United States. Furthermore, at last month's American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, Florida, HLB Therapeutics met with key partners and confirmed their continued interest. -"In addition to the anticipation for the SEER-2 clinical trial, which has already progressed considerably, securing patents related to the RGN-259 manufacturing process in major countries is significant in that it gives us important intellectual property (IP) that will further strengthen our position in future negotiations with global big pharma companies." https://www.news1.kr/bio/pharmaceutical-bio/5978540
1 · Reply
dontu1dr
dontu1dr Nov. 13 at 3:53 PM
$RGRX 2nd TB4 EU Trial #: (do a search on it) 2024-518969-98-00 Medical condition(s)Neurotrophic Keratopathy Trial PhaseTherapeutic confirmatory (Phase III) Trial Duration: Start of trial 04/11/2025 Estimated end of trial date in EU/EEA: 25/11/2025 or November 25, 2025 Estimated global end date of the trial: 25/11/2025 or November 25, 2025 At this point in time, looks like ITALY is the only point recruiting vs SPAIN & POLAND, which might infer they’re keeping a “tighter control” on this Euro Trial. The Donker
0 · Reply
12e456789o
12e456789o Nov. 6 at 7:45 PM
$RGRX Here's what I am seeing for HLB Thera. The entire correction after 2018 high is double zigazag or abc-x-abc. Chart is currently finishing the last c wave which is a 5 wave sequence. Monday's high cemented the 3rd wave bottom. 4th wave could now be completed or could continue up a little further. Either way there should be one more wave down that will take the price below 2780 to finish a multi year flat.
0 · Reply
dontu1dr
dontu1dr Oct. 22 at 12:18 PM
$RGRX It will be interesting to read fda's "fda plausible mechanism pathway" to be published in a week or two in the New England Journal, won't it? This would/could negate the NK Euro Trial results being needed. And when you consider "dompe's oxervate" price, complexity of using for seniors, side effects, ect--- Humanitarian decision would make sense/cents. Also, take in consideration RFK Jr's interest in peptides... Just because most folks don't follow such things, doesn't mean BIG PHARMA is ignorant about what is happening behind the scenes. ALSO, don't forget about Wayne States world patent app: https://patents.google.com/patent/WO2024233903A1/en?oq=WO%2f2024%2f233903 A real break-thru for diabetic eye problems... read that patent app if you have time... All this makes sense/cents doesn't it? THE DONKER
1 · Reply
NachoQueso
NachoQueso Oct. 18 at 9:28 PM
$RGRX Curious if there have been any notable updates or shifts with RGRX lately. Appreciate any insights or quick recaps from those who’ve been following more closely!
0 · Reply
dontu1dr
dontu1dr Aug. 15 at 5:39 PM
$RGRX Keep in mind that the Euro Trial ended: Date of completion: 04/02/2025 And HLB Thera reported the "oral/audible" placebo problem call on 6/24/25 with no paperwork (HLB THERA claims) ... ---almost 2 full months after trial ended... What you need to understand, in Europe you have to report the true trial results "one year after trial ended" or by April 2026... That's the proverbial pharma "show me what your holding in your hand" date in Europe... UNTIL APRIL 2026: EXACT TRIAL RESULTS are known only by HLB THERA... Come APRIL 2026, we'll see the true reported trial results OF RECORD... It'll be interesting to see what they actually disclose on 4/2/026... And what happens in the interim? Also, did you notice that Immunomic Therapeutics (owned by HLB Thera) looks like it's set up to go PUBLIC... review their: ---SEC FILINGS (amount of money invested and when***) --- recent changes in ***Directors***(Won S Yang is back) and recent management changes... Interesting times... THE DONKER
1 · Reply
ByeAndHold
ByeAndHold Aug. 8 at 12:58 AM
$RGRX From JJ: Communicating additional trial information is up to our Korean partners as they are managing and funding the entire effort. I do not think we will hear any more specific data until we receive top line data from SEER-2, but that's just my expectation. No update on negotiations with third parties but my sense is that there won't be any until SEER-2 has topline info, as that obviously is critical to any potential deal. Yes, it's be a long road and slower than we all anticipated. I intend to hang in there until we find out one way or the other if RGN-259 is an effective therapy for NK. J.J. Finkelstein President & CEO RegeneRx Biopharmaceuticals, Inc. 301.208.9191
0 · Reply
12e456789o
12e456789o Jul. 30 at 9:58 PM
$RGRX HLB Thera at an interesting juncture. Currently just shy of A=C on a daily closing basis. Also previous (blue) wave 2 at 3629 should also offer support. Turn here quite possible.
0 · Reply
dontu1dr
dontu1dr Jul. 20 at 3:24 PM
$RGRX I think this article will kinda "tie together the future pathways for orphan drugs" for investors: https://www.knobbe.com/blog/rare-disease-therapies-gain-momentum-with-regulatory-support-and-continued-market-growth/ NOTEABLE QUOTES: "the orphan drug market is currently valued at about $216 billion USD.[xv] The market is expected to continue to grow at a compound annual growth rate (CAGR) of between about 10-12%, reaching valuation in excess of $500 billion by 2032." While it remains to be seen how the FDA will streamline the process for regulatory approval, the promised conditional approvals combined with expanded post-market surveillance may soon redefine how novel rare-disease therapies reach patients. THINK: Conditional approvals Phase IV studies afterwards This situation would UNLOCK: TB4 NK (orphan) EYE wouldn't it??? But think abit folks... Same situation would apply to: RGN-137 for EB or Epidermolysis Bullosa (orphan) skin -which has been patented: https://patents.google.com/patent/US11179443B2/en?assignee=hlb+therapeutics&oq=hlb+therapeutics clinical trials setup and couldn't recruit: -did JJ allude to this in his latest letter???
1 · Reply
dontu1dr
dontu1dr Jul. 18 at 3:42 PM
$RGRX read the following article and get the gist of what's happening in CBER (TB4 is a biologic), FDA, & PHS... TB4 NK is not in some "binary event"--- More possibilities now than any time in the past if you understand what is said in this article: https://www.biospace.com/fda/fdas-prasad-vows-to-make-rare-disease-drugs-available-at-first-sign-of-promise NOTABLE QUOTES: -Prasad said, and make use of surrogate endpoints to get new medicines to patients before they clear the traditional efficacy bar for authorization. -“We will take action at the first sign of promise for rare diseases. We’re not going to wait,” Prasad said. -FDA Commissioner Marty Makary: "The FDA will grant conditional approval to “scientifically plausible” rare disease medicines based on data from single-arm trials when it is not feasible for companies to run randomized studies." GET IT? "BASED on DATA from SINGLE ARMS TRIALS" which would solve eye trials with tb4 eye Things are anything but the same "ol', same ol" THE DONKER
0 · Reply
dontu1dr
dontu1dr Jul. 16 at 4:29 PM
$RGRX SOME QUOTES: The FDA is eyeing a “new pathway” for rare disease drugs, potentially allowing for their approval even without data from a randomized, controlled clinical trial, recently confirmed FDA Commissioner Marty Makary said in an interview on Friday. Speaking on The Megyn Kelly Show in his first major interview since taking the reins at the FDA, Makary said the agency will open a new regulatory pathway based on what he called a “plausible mechanism,” focusing mainly on rare or incurable diseases that affect “a small number of people.” If there is an investigational drug, Makary explained, “that makes sense physiologically. The mechanism is scientifically plausible that this treatment would help these individuals.” The FDA could approve that therapy on “a conditional basis . . . even though we don’t have a randomized controlled trial because it’s not feasible.” YOU NEED TO READ UP ON THIS A BIT, THE DONKER
1 · Reply